TopNewsOn
Business

Lilly Buying Spree Surpasses $32B

Bloomberg·November 18, 2026

Bloomberg’s Madison Muller joins Dani Burger on “Bloomberg Deals.”  Eli Lilly agreed to buy closely held Calytrix Bio in a deal that could be worth up to $1.5 billion, the latest in the drugmaker’s $32 billion wave of acquisitions in 2026 as it builds out its cancer and immunology businesses. (Source: Bloomberg)

Read the full story at Bloomberg →